<unk>  is used for the treatment of infections caused by influenza A and influenza B viruses, but in otherwise-healthy individuals, benefits overall appear to be small. It decreases the risk of one's getting symptomatic, but not asymptomatic influenza. The combination of diagnostic uncertainty, the risk for virus strain resistance, possible side effects and financial cost outweigh the small benefits of<unk>  for the prophylaxis and treatment of healthy individuals. Since then, genes expressing resistance to<unk>  were found in Chinese people infected with avian influenza A H7N9 during treatment with<unk> . Treatment In otherwise-healthy individuals, benefits overall appear to be small.<unk>  shortens the duration of symptoms of influenza-like illness (unconfirmed influenza or 'the flu') by less than a day. In children with asthma there was no clear effect on the time to first alleviation of symptoms. Whether it affects the risk of one's need to be hospitalized or the risk of death is not clear. There is no proof that<unk>  reduced hospitalizations or pneumonia and other complications of influenza, such as bronchitis, middle ear infection, and sinusitis.<unk>  did not reduce the risk of self reported investigator mediated pneumonia or radiologically confirmed pneumonia in adults. The effect on pneumonia in children was also not significant. Prevention Low to moderate evidence indicates it decreases the risk of one's getting influenza by 1 to 12% in those exposed. Prophylaxis trials showed that<unk>  reduced the risk of symptomatic influenza in individuals and households, but there was no evidence of an effect on asymptomatic influenza or on other, influenza-like illnesses. Also there was no evidence of reduction of risk of person-to-person spread of the influenza virus. The evidence for a benefit in preventing influenza is weak in children, with concerns of publication bias in the literature. Resistance As of 2009, no influenza had shown any signs of resistance in the US. A meta-analysis from 2011 found that<unk>  resistance had been rarely reported. Antiviral resistance can emerge during or after treatment with antivirals in certain people (e.g., immunosuppressed). In 2013 genes expressing resistance to<unk>  (and oseltamivir) were found in Chinese patients infected with avian influenza A H7N9.
Zanamivir
Oseltamivir
Peramivir
Quifenadine
Inadine
Rimantadine
Umifenovir
Faricimab